Scancell (LON:SCLP) Shares Up 29.8% – Here’s Why

Scancell Holdings plc (LON:SCLPGet Free Report)’s stock price was up 29.8% during trading on Monday . The stock traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.14). Approximately 10,537,342 shares traded hands during mid-day trading, an increase of 1,073% from the average daily volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Price Performance

The business’s 50-day simple moving average is GBX 8.43 and its two-hundred day simple moving average is GBX 10.88. The stock has a market cap of £113.93 million, a price-to-earnings ratio of -16.86 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01.

Scancell (LON:SCLPGet Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. Research analysts expect that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.

About Scancell

(Get Free Report)

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

Further Reading

Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.